Combined Inhibition of MDM2 and BCR-Abl Tyrosine Kinase Targets Chronic Myeloid Leukemia Stem/Progenitor Cells in a Murine Model

Haematologica - Italy
doi 10.3324/haematol.2019.219261
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Adoptive Immunotherapy of BCR-ABL-induced Chronic Myeloid Leukemia-Like Myeloproliferative Disease in a Murine Model

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

Incidence and Outcome of BCR‐ABL Mutated Chronic Myeloid Leukemia Patients Who Failed to Tyrosine Kinase Inhibitors

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

Differential Genomics and Transcriptomics Between Tyrosine Kinase Inhibitor-Sensitive and -Resistant BCR-ABL-dependent Chronic Myeloid Leukemia

Oncotarget
Oncology
2018English

BCR-ABL Tyrosine Kinase

Science-Business eXchange
2012English

Chronic Myeloid Leukemia Stem Cells Possess Multiple Unique Features of Resistance to BCR-ABL Targeted Therapies

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2007English

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

Haematologica
Hematology
2015English

Current Status of ABL Tyrosine Kinase Inhibitors Stop Studies for Chronic Myeloid Leukemia

Stem Cell Investigation
2016English

Tyrosine Kinase Inhibition in Acute Myeloid Leukemia

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2013English

Inhibitory Effects of Omacetaxine on Leukemic Stem Cells and BCR-ABL-induced Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Mice

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy